

> d his full

(FILE 'HOME' ENTERED AT 14:26:23 ON 16 OCT 2002)

FILE 'CAPLUS, MEDLINE, EMBASE, BIOSIS' ENTERED AT 14:27:03 ON 16 OCT 2002
L1 1659 SEA ABB=ON PLU=ON (TNF OR TUMOR NECROSIS FACTOR) (5A)
 (ANTAGONIST) (P) (MALIGNAN? OR CANCER OR TUMOR OR METSTASIS OR
 NEOPLAS?)
L2 831 DUP REM L1 (828 DUPLICATES REMOVED)
L3 81 SEA ABB=ON PLU=ON L2 (P) (MONOCLONAL ANTIBODY OR TNF BINDING
 PROTEIN OR ANTIBODY FRAGMENT OR FUSION PROTEIN)
L4 81 DUP REM L3 (0 DUPLICATES REMOVED)
L5 1 SEA ABB=ON PLU=ON L4 AND (PERILESIONAL? OR INTRALESIONAL?)
 D L5 IBIB KWIC
L6 9 SEA ABB=ON PLU=ON (TNF OR TUMOR NECROSIS FACTOR) (5A)
 (ANTAGONIST OR ANTIBODY OR FUSION PROTEIN) AND (PERILESIONAL?
 OR INTRALESIONAL?)
L7 6 DUP REM L6 (3 DUPLICATES REMOVED)
 D L7 IBIB
 D L7 IBIB 2-7
 D L7 IBIB 2-7 KWIC
L8 9 SEA ABB=ON PLU=ON L6 AND (NEUROLOGICAL OR DEGENRATIVE OR
 CANCER OR TUMOR OR METASTASIS OR MALIGNAN?)
L9 6 DUP REM L8 (3 DUPLICATES REMOVED)
 D L9 IBIB KWIC 1-

=> d his full

(FILE 'HOME' ENTERED AT 14:26:23 ON 16 OCT 2002)

L1 FILE 'CAPLUS, MEDLINE, EMBASE, BIOSIS' ENTERED AT 14:27:03 ON 16 OCT 2002
1659 SEA ABB=ON PLU=ON (TNF OR TUMOR NECROSIS FACTOR) (5A)
(ANTAGONIST) (P) (MALIGNAN? OR CANCER OR TUMOR OR METSTASIS OR
NEOPLAS?)
L2 831 DUP REM L1 (828 DUPLICATES REMOVED)
L3 81 SEA ABB=ON PLU=ON L2 (P) (MONOCLONAL ANTIBODY OR TNF BINDING
PROTEIN OR ANTIBODY FRAGMENT OR FUSION PROTEIN)
L4 81 DUP REM L3 (0 DUPLICATES REMOVED)
L5 1 SEA ABB=ON PLU=ON L4 AND (PERILESIONAL? OR INTRALESIONAL?)
D L5 IBIB KWIC
L6 9 SEA ABB=ON PLU=ON (TNF OR TUMOR NECROSIS FACTOR) (5A)
(ANTAGONIST OR ANTIBODY OR FUSION PROTEIN) AND (PERILESIONAL?
OR INTRALESIONAL?)
L7 6 DUP REM L6 (3 DUPLICATES REMOVED)
D L7 IBIB
D L7 IBIB 2-7
D L7 IBIB 2-7 KWIC
L8 9 SEA ABB=ON PLU=ON L6 AND (NEUROLOGICAL OR DEGENRATIVE OR
CANCER OR TUMOR OR METASTASIS OR MALIGNAN?)
L9 6 DUP REM L8 (3 DUPLICATES REMOVED)
D L9 IBIB KWIC 1-

L10 FILE 'CAPLUS, MEDLINE' ENTERED AT 14:40:49 ON 16 OCT 2002
254 SEA ABB=ON PLU=ON (PERILESIONAL? OR INTRELESIONAL?) AND
(CANCER OR MALIGNANCY OR TUMOR OR NEOPLAS? OR METSTASIS OR
NEURODEGENRATIVE OR NEUROLOGICAL)
L11 100 SEA ABB=ON PLU=ON (PERILESIONAL? OR INTRELESIONAL?) AND
(INHIBIT? OR TREAT? OR PREVENT? OR ALLEVIAT? OR REDUC?) (P)
(CNS OR CENTRAL NERVOUS SYTEM OR CANCER OR MALIGNANCY OR TUMOR
OR NEOPLAS? OR METSTASIS OR NEURODEGENRATIVE OR NEUROLOGICAL)
L12 79 DUP REM L11 (21 DUPLICATES REMOVED)
L13 25 SEA ABB=ON PLU=ON (PERILESIONAL? OR INTRELESIONAL?) (P)
(INHIBIT? OR TREAT? OR PREVENT? OR ALLEVIAT? OR REDUC?) (P)
(CNS OR CENTRAL NERVOUS SYTEM OR CANCER OR MALIGNANCY OR TUMOR
OR NEOPLAS? OR METSTASIS OR NEURODEGENRATIVE OR NEUROLOGICAL)
L14 760 SEA ABB=ON PLU=ON (PERILESIONAL? OR INTRALESIONAL?) (P)
(INHIBIT? OR TREAT? OR PREVENT? OR ALLEVIAT? OR REDUC?) (P)
(CNS OR CENTRAL NERVOUS SYTEM OR CANCER OR MALIGNANCY OR TUMOR
OR NEOPLAS? OR METSTASIS OR NEURODEGENRATIVE OR NEUROLOGICAL)
L15 447 SEA ABB=ON PLU=ON (PERILESIONAL? OR INTRALESIONAL?) (P)
(INJECT? OR ADMINIST?) (P) (INHIBIT? OR TREAT? OR PREVENT? OR
ALLEVIAT? OR REDUC?) (P) (CNS OR CENTRAL NERVOUS SYTEM OR
CANCER OR MALIGNANCY OR TUMOR OR NEOPLAS? OR METSTASIS OR
NEURODEGENRATIVE OR NEUROLOGICAL)
L16 353 DUP REM L15 (94 DUPLICATES REMOVED)
L17 2799 SEA ABB=ON PLU=ON (PERILESIONAL? OR INTRALESIONAL?) (5A)
(INJECT? OR ADMINIST?)
L18 67 SEA ABB=ON PLU=ON (PERILESIONAL? OR INTRALESIONAL?) (5A)
(INJECT? OR ADMINIST?) (P) (ANTIBODY OR ANTAGONIST OR FUSION
PROTEIN)
L19 608851 SEA ABB=ON PLU=ON (INHIBIT? OR TREAT? OR PREVENT? OR
ALLEVIAT? OR REDUC?) (P) (CNS OR CENTRAL NERVOUS SYTEM OR
CANCER OR MALIGNANCY OR TUMOR OR NEOPLASM OR METSATSIS OR
NEURODEGENRATIVE OR NEUROLOGICAL)
L20 28 SEA ABB=ON PLU=ON L18 (P) L19
L21 22 DUP REM L20 (6 DUPLICATES REMOVED)
D L21 IBIB KWIC 1-

21 ANSWER 20 OF 22 MEDLINE
ACCESSION NUMBER: 87041518 MEDLINE
DOCUMENT NUMBER: 87041518 PubMed ID: 3464977
TITLE: Regression of cutaneous metastatic melanoma by
intraleisional injection with human monoclonal antibody to
ganglioside GD2.
AUTHOR: Irie R F; Morton D L
CONTRACT NUMBER: CA12582 (NCI)
CA29605 (NCI)
CA30647 (NCI)
SOURCE: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE
UNITED STATES OF AMERICA, (1986 Nov) 83 (22) 8694-8.
Journal code: 7505876. ISSN: 0027-8424.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 198612
ENTRY DATE: Entered STN: 19900302
Last Updated on STN: 19970203
Entered Medline: 19861217
AB In this study we used human monoclonal **antibody** (Hu-mAb) L72 as
an intratumoral injection of cutaneous metastasis of melanoma to study its
anti-**tumor** effects in human patients. Hu-mAb L72 was developed
by transforming peripheral blood lymphocytes from a melanoma patient in
vitro with. . . a strong cytotoxic effect on human melanoma cells in
the presence of complement. Patients with cutaneous metastatic melanoma
were given **intraleisional injections** on a daily or
weekly injection schedule. Regression was seen in all **tumors**
except in those of two patients whose **tumors** were shown to have
low antigenicity. Histopathological data showed **tumor**
degeneration, fibrosis, free melanin, and some degree of lymphocyte or
macrophage infiltration. One patient with melanoma satellitosis
treated with Hu-mAb showed complete regression with no sign of
recurrence 20 months after the initial **treatment**. With the
exception of mild erythema, no side effects were observed in any patient.

L21 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2002 ACS DUPLICATE 6
ACCESSION NUMBER: 1988:184932 CAPLUS
DOCUMENT NUMBER: 108:184932
TITLE: Effects of intralesional injections of interferons-.alpha. on xenografts of human mammary carcinoma cells (BT 20 and MCF-7)
AUTHOR(S): Ozzello, Luciano; Habif, David V.; De Rosa, Carolyn M.; Cantell, Kari
CORPORATE SOURCE: Dep. Surg., Columbia Univ., New York, NY, 10032, USA
SOURCE: J. Interferon Res. (1988), 8(2), 207-15
CODEN: JIREDJ; ISSN: 0197-8357
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The effects of **intralesional injections** of human natural and recombinant interferons-.alpha. (nIFN-.alpha. and rIFN-.alpha.A) were studied in nude mice bearing bilateral xenografts of human mammary carcinoma cells (BT 20, MCF-7). One **tumor** of each animal received **intralesional injections**, while the contralateral **tumor** was left undisturbed. Thus, the injected **tumors** were subjected to the local action of the IFNs, whereas the opposite ones were exposed to the systemic effects of the IFNs seeping into the s.c. tissue following the intratumoral injection. When used singly these IFNs exerted an **inhibitory** effect on the growth of both injected and contralateral **tumors**, but failed to cause complete regression. Many of the cells of **treated** BT 20 xenografts showed morphol. alterations (increased cell vol. and nuclear pleomorphism) as compared to the untreated controls. Morphol. alterations in MCF-7 **tumors** were difficult to assess because of the inherent pleomorphism of these cells. The immunoreactivity of BT 20 and MCF-7 **tumors** to monoclonal **antibodies** directed against milk fat globule proteins and against HLA antigens was not appreciably affected by **treatment** with these IFNs. This study confirms that **intralesional injections** of human IFNs-.alpha. partially **inhibit** the growth of human breast **cancer** xenografts, probably through a direct effect on the carcinoma cells. Under the present exptl. conditions, the intralesional and the s.c. routes of administration appear to offer comparable antitumor effectiveness.

WEST Search History

DATE: Wednesday, October 16, 2002

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
	side by side		result set
<i>DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=OR</i>			
L7	(localized or intratumoral or intralesional or perilesional) same (anti-tnf or tnf adj binding adj protein or tnf adj antagonist or tnf adj2 fusion adj protein)	30	L7
L6	L2 and (tnf or tumor adj necrosis adj factor) adj5 (antagonist or antibody or fusion adj protein or binding adj protein)	5	L6
L5	L2 and (tnf or tumor adj necrosis adj factor) (5a) (antagonist or antibody or fusion adj protein or binding adj protein)	564694	L5
L4	sp.govL3	0	L4
L3	L2 and (tnf or tumor adj necrosis adj factor) (intralesional\$ or perilesional\$ or intratumoral\$ or localized) adj5	57	L3
L2	(administer or administration or inject\$) same (neurological or cancer or cns or neurodegenerative metastasis or tumor) adj5 (treat\$ or prevent\$ or reduc\$ or alleviat\$ or inhibit\$ or regress\$)	143	L2
L1	(intralesional\$ or perilesional\$ or intratumoral\$ or localized) adj5 (administer or administration or inject\$) same (neurological or cancer or cns or neurodegenerative metastasis or tumor)	598	L1

END OF SEARCH HISTORY